Medical Device News Magazine

Medsenic, a Subsidiary of BioSenic SA, Extends Key Patent to the United States

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

BioSenic (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell repair therapy, today announces the filing of the continuation patent application US 18/763,376 with the United States Patent & Trademark Office (USPTO) to provide protection for the use of arsenic trioxide (ATO) for the prevention and treatment of sepsis syndrome.

The patent application seeks to cover the use of Medsenic’s ATO platform, to prevent or alleviate the cytokine storm associated with systemic infections of various origins but sharing a common set of key symptoms (such as persistent hypotension, hyperthermia or hypothermia, leukocytosis or leukopenia, and thrombocytopenia) with dramatic short-term health consequences. Similar protection may lead to the filing of further specific divisional applications, in particular at the European Patent Office (EPO).

The ever-growing intellectual property portfolio is part of a strategy to build strong and meaningful protection around its lead product, ATO, paving the way for clinical and commercial development by the company and its partners, particularly in the field of autoimmunity.

The new patent, now being extended by Medsenic in the USA, covers two main areas of immediate application. The first is in immune- and autoimmune-related diseases – specifically BioSenic’s current lead project, chronic GvHD, and later systemic sclerosis and systemic lupus erythematosus. The second is oncology, where ATO has already demonstrated exceptional results in patients, including complete remissions in acute promyelocytic leukaemia. The growing patent family will support Medsenic/BioSenic’s plans for international clinical trials in pathologies with unmet medical needs. The company’s long-term goal is to seek market access approvals for its various formulations, optimizing the original properties of arsenic salts, alone or in combination.

François Rieger, PhD, Chairman and CEO of BioSenic said: “The current effort to improve the field of indications and a broader intellectual property for the use of original formulations and composition of matter related to the extraordinary properties of arsenic salts should give a dramatic impetus to the clinical and commercial development of the company. Arsenic salts are now found to exhibit critical and very original biological properties that should help provide new ways to treat diseases of the immune system and, further, cancer conditions with no effective medical treatment. It is of great interest that pharmacological formulations containing arsenic salts are often found to redirect organisms towards normal functioning of various cells and organs and restore homeostasis. We are delighted to be opening new chapters in the continuing global effort to control chronic or fatal diseases for which there is no real cure.”

The expected availability of both an intravenous and an oral formulation combining arsenic and copper puts BioSenic in a unique position to build on preclinical successes in chosen areas of applications. Medsenic/BioSenic should be able to continue a successful clinical development involving proprietary original formulations with arsenic and new active ingredients such as metal ions- increasing the efficacy of its products and minimizing side effects.

Medsenic’s worldwide patent family already includes a patent granted by the European Union Intellectual Property Office (EP3972613) in April 2023, and others by the China National Intellectual Property Administration in August 2023, by the Australian Patent Office in December 2023 and by Canada in January 2024 (3,138,472).

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”